In this case the antitumor vaccine targets the tumor-specific antigen brachyury, which is an embryonic transcription factor that becomes re-activated in malignant cells to promote tumor migration through the epithelial–mesenchymal transition (EMT) [167]. This evidence concerns the gene TBX1 and neoplasm.